ActiveAtlas Opportunity Score 89/100
HT942526NFRPEHDA
Defense Health Agency FY26 Neurofibromatosis Exploration-Hypothesis Development Award (HT942526NFRPEHDA)
FY26 Neurofibromatosis Research Program Exploration-Hypothesis Development Award supports innovative, high-risk, high-gain NF research. The mandatory pre-application was due September 8, 2026 at 5:00 PM ET; full applications from applicants that completed that step are due September 22, 2026 at 11:59 PM ET.
FundingApproximately $1.28 million for about eight awards. Total-cost cap: $160,000 per award. Maximum period: two years. Cost sharing is not required.
DeadlineRequired pre-application was September 8, 2026 at 5:00 PM Eastern Time. Full application deadline for applicants that completed that step: September 22, 2026 at 11:59 PM Eastern Time.
Last verifiedSeptember 15, 2026
Required next actionDo not initiate new applicant outreach for this cycle because the mandatory September 8 pre-application deadline has passed. Route only already-preapplied NF exploratory research teams that can verify timely first-stage submission and are completing the September 22 full application.
Broad Eligibility
Broad organization eligibility, including domestic and foreign, for-profit and nonprofit, public and private entities. Investigators at all academic levels, including postdoctoral fellows or equivalent, may serve as PI. Preliminary data are encouraged but not required. Cost sharing is not required.
Atlas Analysis
Atlas Opportunity Score 89/100. Accessible exploratory NF research mechanism with broad organization and PI eligibility and no required preliminary data, but the mandatory September 8 pre-application deadline has passed. Classification: Partner-Led / Already-Preapplied NF Exploratory Research Team.
The Defense Health Agency Congressionally Directed Medical Research Programs has opened HT942526NFRPEHDA, FY26 Neurofibromatosis Research Program Exploration-Hypothesis Development Award. The mechanism supports initial exploration of innovative, high-risk, high-gain, potentially groundbreaking concepts in neurofibromatosis research and is intended to lay groundwork for future scientific investigation.
Submission timing: The required pre-application Letter of Intent was due September 8, 2026 at 5:00 PM Eastern Time. Full application deadline: September 22, 2026 at 11:59 PM Eastern Time. Only applicants that timely completed the mandatory first-stage submission may proceed this cycle.
Funding: CDMRP expects approximately $1.28 million for about eight awards, with a total-cost cap of $160,000 per award and a maximum two-year period of performance. Cost sharing is not required.
Eligibility: Eligible organizations include domestic and foreign, for-profit and nonprofit, public and private entities. Investigators at all academic levels, including postdoctoral fellows or equivalent, may be named PI. Investigators do not have to be from academic institutions and may serve as PI on only one FY26 NFRP EHDA application.
Research controls: Projects should present a well-formulated, testable hypothesis supported by strong scientific rationale and study design. Innovation is central. Preliminary and/or published data are encouraged but not required.
Atlas fit: Broad organization and investigator eligibility creates potential fit for qualified research partners, but the expired mandatory pre-application prevents a new current-cycle pursuit. Preferred posture: Partner-Led / Already-Preapplied NF Exploratory Research Team. Do not initiate new applicant outreach for this cycle; route only organizations that can verify timely September 8 pre-application submission.
Source verificationOfficial government source · files.simpler.grants.govAtlas last verified this record September 15, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
